



# 21<sup>st</sup> Century Therapeutics, Inc.

1366 HILTON RD.  
FERNDALE, MI 48220  
USA  
(248) 545-0595  
21-cti.com

For Immediate Release

May 20, 2012

## Pharmaceutical Research Firm Signs Agreement with a Chinese Firm for Drug Development

Ferndale, Michigan based 21<sup>st</sup> Century Therapeutics, Inc. (21CTI) signed an agreement with the Chinese pharmaceutical company, Chendu Xin Fanyu Biomedical (XFY), to develop a small-molecule Tumor Necrosis Factor- $\alpha$  (TNF- $\alpha$ ) inhibitor as a chemoprotector to reduce side effects induced by platinum anticancer drugs. According to 21CTI's CEO, Dr. Frederick Valeriote, this is the first intercontinental agreement signed by 21CTI. "This collaboration will help us speed up the preclinical development of UTL-5g as a novel chemoprotector", said Valeriote.

According to 21CTI's President, Dr. JJ Shaw, platinum drugs have been widely prescribed for many years to treat a variety of solid tumors, but platinum drugs induce a number of side effects including nephrotoxicity (kidney damage), hepatotoxicity (liver damage), and hematotoxicity (toxicity to blood cells). Based on the recently completed studies by 21CTI, pretreatment of UTL-5g reduced nephrotoxicity and hepatotoxicity induced by cisplatin, and increased blood platelet counts in mice. Furthermore, pretreatment of UTL-5g increased the therapeutic efficacy of cisplatin against HCT-15 human colon cancer cells inoculated into mice. The successful studies by 21CTI resulted in a patent application filed in the US Patent and Trademark Office (PTO), and a scientific paper published in the Journal of Experimental Therapeutics and Oncology (2011, volume 9 p. 129-137). With the newly signed collaborative agreement, 21CTI expects to add more preclinical data from XFY and shorten the preclinical development time. In addition, certain milestone payments will be made from XFY to 21CTI. In exchange, XFY will have the right to develop and market the same products in China and Japan.

21CTI is a private pharmaceutical discovery and development company, specializing in cancer and immune-mediated diseases. In addition to UTL-5g, several other anticancer agents and immune modulators are in preclinical development.

This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchanges rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. 21CTI's management does not undertake any responsibility to update the forward-looking statements contained in this release.

Contact: Frederick Valeriote (586) 863-8298 or JJ Shaw (734) 330-6052

Website: [www.21-cti.com](http://www.21-cti.com)

e-mail: [jshaw@21-cti.com](mailto:jshaw@21-cti.com)

